BioSpace News Archive

TORONTO, June 3, 2024 /PRNewswire/ - Apotex Inc. announced the successful completion of its acquisition of Searchlight Pharma Inc., a leading Canadian specialty innovative branded pharmaceutical company.

Aethlon Medical, Inc. (Nasdaq: AEMD) today provided the following update on its planned phase 1 safety, feasibility and dose-finding clinical trials of its Hemopurifier® in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® or Opdivo®.

McKesson Corporation announced that the McKesson board of directors has elected Dr. Deborah Dunsire as a director and member of the Compensation and Talent Committee and Finance Committee, effective June 3, 2024.

Molecular Templates, Inc. today provided an update on its clinical-stage programs.

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the presentation of three posters at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL today and online.

GSK plc (LSE/NYSE: GSK) today announced updated, longer-term results from the phase II supported collaborative study with Memorial Sloan Kettering Cancer Center (MSK) evaluating Jemperli (dostarlimab-gxly) as a first-line treatment—as an alternative to surgery—for mismatch repair deficient (dMMR) locally advanced rectal cancer.

Grace Science, LLC announced today that the IND for GS-100, an AAV9 gene therapy for NGLY1 Deficiency, was accepted into the FDA’s Support for clinical Trials Advancing Rare disease Therapeutics (START) Pilot Program.

The Thermo Scientific™ Stellar™ mass spectrometer combines speed and sensitivity to advance precision medicine.

Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO ® Annual Meeting Highlighting Opdivo and Opdivo -based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer.

ASCO Annual Meeting – Massive Bio and Un Ensayo Para Mi (UEPM), a premier clinical trial search platform in Latin America, are excited to announce an expanded partnership.